NEW YORK (GenomeWeb) – GenePOC today announced it has received CE marking for its Revogene instrument and tests for Group B Streptococcus and Clostridium difficile for marketing in Europe and other geographies that recognize the designation.

The Quebec City-based rapid molecular devices firm, which is part of Debiopharm, added that it has completed clinical trials for GBS for the US Food and Drug Administration and expects to start clinical trials for C. difficile by mid-January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.